Cytomegalovirus Treatment Market size was valued at $503 million in 2020, growing at a CAGR of 6.0% during the forecast period 2021-2026. Cytomegalovirus (CMV) is the most commonly transmitted herpes virus which remains dormant in the human body. It is a communicable disease and it can infect people of all ages globally. Cytomegalovirus spread through direct contact with such as saliva, blood, urine, semen, and breast milk. The symptoms of Cytomegalovirus are fatigue, fever, sweats, muscle aches, sore throat, headache and others. There many medicines are available in the market for the treatment of cytomegalovirus such as ganciclovir, valganciclovir, foscarnet, cidofovir and others. Increasing prevalence of CMV retinitis and congenital CMV infection coupled with increasing public awareness related to herpes virus infections is major factor driving the growth of the market. Moreover, growing prevalence of viral infection among AIDS patients further enhance the overall market demand for Cytomegalovirus Treatment during the aforesaid period.
Key Takeaways
In 2020, North America dominates the Cytomegalovirus Treatment Market owing to rising government funding and increasing research in the area.
Increasing innovation and development in Cytomegalovirus Treatment across the globe is driving the market growth of Cytomegalovirus Treatment.
Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the Cytomegalovirus Treatment Market report.
Adverse Effects and Risks Related to Cytomegalovirus Drugs are challenging the growth of the market.
Cytomegalovirus Treatment Market Segment Analysis- By Drugs
Based on the drugs, Cytomegalovirus Treatment Market is segmented into Ganciclovir, Valganciclovir, Foscarnet, Cidofovir, others. The Ganciclovir segment is estimated to dominate the market during the period 2021-2026. This is attributed to it is widely used as anti-viral drug to treat and prevent infections. Furthermore, Ganciclovir is most effective drug and show quick result. The Valganciclovir, segment is forecast to be the fastest-growing segment and is projected to grow at a CAGR of 5.6% during the period 2021-2026. This is mainly owing to Valganciclovir is simple and convenient and offer potential for improved patient compliance.
Cytomegalovirus Treatment Market Segment Analysis- By Application
Based on the application, Cytomegalovirus Treatment Market is segmented into Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, other. In 2020, Stem Cell Transplantation is estimated to hold major share in the market. This is mainly rising funding from the government as well as private organization to support stem cell therapy clinical trial. Moreover, declining prices of stem cell therapies which leads to rising preference of buyers towards cell therapy.Also, Organ Transplantation is projected to grow with a CAGR of 4.9% over the period 2021-2026. This is owing to it rising number of organ transplants across the globe.
Cytomegalovirus Treatment Market Segment Analysis- By Geography
North America dominated the Cytomegalovirus Treatment market share accounting for 40% of the market in 2020. This is mainly owing to increasing prevalence of cytomegalovirus infection in this region. According to, Centres for Disease Control and Prevention (CDC), in U.S. it is most common infection ailment cause of birth defects.
However, the Asia-Pacific region is projected to be the fastest-growing over the period 2021-2026. This is owing to rising expenditure on healthcare coupled with rising aging population.
Cytomegalovirus Treatment Market Drivers
Increasing Prevalence of Cytomegalovirus (CMV) Infection
Increasing prevalence of cytomegalovirus (CMV) infection across the globe is driving the growth of Cytomegalovirus Treatment market. According to, Centres for Disease Control and Prevention (CDC), in U.S. one in every 150 infants are born with cytomegalovirus (CMV) infection. Moreover, increasing prevalence of viral infections among AIDS patients is also set to increase the market growth.
Rising Number of Organ Transplantation
Rising number of organ transplantation across the globe which leads to rise in cytomegalovirus (CMV) infection among patients is also driving the market. According to, World Health Organization (WHO), around 100, 800 solid organ transplants are performed every year worldwide. Also, rising awareness about treatment of cytomegalovirus (CMV) infection among the people is also set to the growth of Cytomegalovirus Treatment Market.
Cytomegalovirus Treatment Market Challenges
Adverse Effects and Risks Related to cytomegalovirus drugs causes fever, rash, diarrhea, anemia, and low white blood cell and platelet counts is challenging the market. Along with this stringent regulatory process for drug approval are also further challenging the growth of the market.
Covid-19 Impact
Moreover, the outbreak of COVID-19 around the world has impacted all industries including healthcare industry. Covid- 19 affects the Cytomegalovirus Treatment market including drastic reduction demand owing to lack of visits to healthcare facilities such as hospitals and clinics. Also owing to widespread of coronavirus it affects workforce and staffing issues, procedural prioritisation. These affects Cytomegalovirus Treatment market by cancellation of scheduled visit for primary care at hospitals and reflecting patients concern about infection.
Cytomegalovirus Treatment Market Landscape
Product launches, Merger & Acquisitions, Joint Ventures and R&D activities are key strategies adopted by players in the Cytomegalovirus Treatment Market. Cytomegalovirus Treatment top 10 companies are Chimerix, Clinigen Group PLC., F. Hoffmann-La Roche Ltd., Fresenius Kabi Canada, Genentech Inc., Gilead Sciences, Merck & Co. Inc., Mylan N.V, Teva Canada Limited, and Thermo Fisher Scientific
